Royal Bank of Canada’s Inovio Pharmaceuticals INO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4K | Buy |
4,252
+470
| +12% | +$558 | ﹤0.01% | 6994 |
|
|
2026
Q1 | $6K | Buy |
3,782
+2,093
| +124% | +$3.44K | ﹤0.01% | 6368 |
|
|
2025
Q4 | $3K | Sell |
1,689
-163,791
| -99% | -$361K | ﹤0.01% | 6832 |
|
|
2025
Q3 | $387K | Buy |
165,480
+43,217
| +35% | +$82.7K | ﹤0.01% | 4668 |
|
|
2025
Q2 | $249K | Buy |
122,263
+117,854
| +2,673% | +$226K | ﹤0.01% | 4992 |
|
|
2025
Q1 | $7K | Sell |
4,409
-6,661
| -60% | -$13.4K | ﹤0.01% | 6261 |
|
|
2024
Q4 | $20K | Buy |
11,070
+7,386
| +200% | +$32.7K | ﹤0.01% | 6109 |
|
|
2024
Q3 | $21K | Buy |
3,684
+183
| +5% | +$1.51K | ﹤0.01% | 6092 |
|
|
2024
Q2 | $28K | Buy |
3,501
+2,359
| +207% | +$24.8K | ﹤0.01% | 5919 |
|
|
2024
Q1 | $15K | Sell |
1,142
-5,018
| -81% | -$43.3K | ﹤0.01% | 6033 |
|
|
2023
Q4 | $37K | Sell |
6,160
-320
| -5% | -$1.58K | ﹤0.01% | 6117 |
|
|
2023
Q3 | $31K | Buy |
6,480
+5,265
| +433% | +$29.1K | ﹤0.01% | 6012 |
|
|
2023
Q2 | $7K | Sell |
1,215
-1,150
| -49% | -$9.27K | ﹤0.01% | 6575 |
|
|
2023
Q1 | $23K | Sell |
2,365
-28,071
| -92% | -$479K | ﹤0.01% | 5969 |
|
|
2022
Q4 | $570K | Buy |
30,436
+25,633
| +534% | +$581K | ﹤0.01% | 3994 |
|
|
2022
Q3 | $99K | Buy |
4,803
+2,117
| +79% | +$54.2K | ﹤0.01% | 5310 |
|
|
2022
Q2 | $55K | Sell |
2,686
-1,093
| -29% | -$30.8K | ﹤0.01% | 5671 |
|
|
2022
Q1 | $163K | Sell |
3,779
-8,739
| -70% | -$394K | ﹤0.01% | 5268 |
|
|
2021
Q4 | $750K | Buy |
12,518
+6,647
| +113% | +$533K | ﹤0.01% | 4108 |
|
|
2021
Q3 | $504K | Buy |
5,871
+1,559
| +36% | +$156K | ﹤0.01% | 4353 |
|
|
2021
Q2 | $480K | Buy |
4,312
+333
| +8% | +$32K | ﹤0.01% | 4328 |
|
|
2021
Q1 | $442K | Buy |
3,979
+1,915
| +93% | +$252K | ﹤0.01% | 4293 |
|
|
2020
Q4 | $219K | Buy |
2,064
+627
| +44% | +$83.5K | ﹤0.01% | 4797 |
|
|
2020
Q3 | $200K | Sell |
1,437
-339
| -19% | -$70.7K | ﹤0.01% | 4552 |
|
|
2020
Q2 | $575K | Sell |
1,776
-696
| -28% | -$112K | ﹤0.01% | 3658 |
|
|
2020
Q1 | $221K | Buy |
2,472
+2,398
| +3,241% | +$148K | ﹤0.01% | 4258 |
|
|
2019
Q4 | $3K | Buy |
74
+32
| +76% | +$963 | ﹤0.01% | 6485 |
|
|
2019
Q3 | $1K | Sell |
42
-2,291
| -98% | -$69.7K | ﹤0.01% | 6457 |
|
|
2019
Q2 | $82K | Sell |
2,333
-7,175
| -75% | -$285K | ﹤0.01% | 4991 |
|
|
2019
Q1 | $426K | Buy |
9,508
+250
| +3% | +$12.6K | ﹤0.01% | 3842 |
|
|
2018
Q4 | $444K | Sell |
9,258
-426
| -4% | -$25.9K | ﹤0.01% | 3804 |
|
|
2018
Q3 | $646K | Buy |
9,684
+425
| +5% | +$23.7K | ﹤0.01% | 3711 |
|
|
2018
Q2 | $436K | Buy |
9,259
+8,759
| +1,752% | +$483K | ﹤0.01% | 3882 |
|
|
2018
Q1 | $28K | Buy |
500
+136
| +37% | +$7.36K | ﹤0.01% | 5320 |
|
|
2017
Q4 | $18K | Sell |
364
-727
| -67% | -$45.1K | ﹤0.01% | 5634 |
|
|
2017
Q3 | $83K | Buy |
1,091
+755
| +225% | +$56.2K | ﹤0.01% | 5133 |
|
|
2017
Q2 | $32K | Sell |
336
-102
| -23% | -$8.72K | ﹤0.01% | 5330 |
|
|
2017
Q1 | $35K | Sell |
438
-4
| -0.9% | -$319 | ﹤0.01% | 5334 |
|
|
2016
Q4 | $37K | Buy |
442
+232
| +110% | +$21K | ﹤0.01% | 5431 |
|
|
2016
Q3 | $24K | Sell |
210
-34
| -14% | -$3.76K | ﹤0.01% | 5474 |
|
|
2016
Q2 | $27K | Sell |
244
-208
| -46% | -$25.3K | ﹤0.01% | 5376 |
|
|
2016
Q1 | $47K | Buy |
452
+417
| +1,191% | +$32.2K | ﹤0.01% | 5157 |
|
|
2015
Q4 | $3K | Sell |
35
-260
| -88% | -$20.7K | ﹤0.01% | 6282 |
|
|
2015
Q3 | $21K | Buy |
295
+276
| +1,453% | +$24K | ﹤0.01% | 5556 |
|
|
2015
Q2 | $2K | Buy |
+19
| New | +$2.03K | ﹤0.01% | 6369 |
|
|
2015
Q1 | – | Sell |
-195
| Closed | -$22K | – | 6265 |
|
|
2014
Q4 | $22K | Buy |
195
+115
| +144% | +$14.1K | ﹤0.01% | 5379 |
|
|
2014
Q3 | $9K | Sell |
80
-21
| -21% | -$2.62K | ﹤0.01% | 5509 |
|
|
2014
Q2 | $13K | Buy |
101
+21
| +26% | +$2.48K | ﹤0.01% | 5328 |
|
|
2014
Q1 | $13K | Sell |
80
-31
| -28% | -$4.45K | ﹤0.01% | 5346 |
|
|
2013
Q4 | $15K | Buy |
111
+31
| +39% | +$3.1K | ﹤0.01% | 5352 |
|
|
2013
Q3 | $8K | Buy |
+80
| New | +$6.71K | ﹤0.01% | 5489 |
|
Other funds holding INO
JT
BCM
ACM
EP
Royal Bank of Canada's INO Position: Q2 2026 in Review
Royal Bank of Canada increased its Inovio Pharmaceuticals (INO) stake by 12% in Q2 2026, buying an estimated $558 and bringing the position to 4,252 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #6994.
Royal Bank of Canada first reported a position in INO in Q3 2013 and has held it in 51 quarters since. The position peaked at $750K in Q4 2021. 103 funds tracked by Wall St. Rank hold INO as of Q2 2026.
- Royal Bank of Canada held 4,252 shares of Inovio Pharmaceuticals worth $4K as of Q2 2026.
- Royal Bank of Canada bought 470 Inovio Pharmaceuticals shares in Q2 2026, an estimated $558.
- Inovio Pharmaceuticals made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #6994 holding.
- Royal Bank of Canada first reported a position in Inovio Pharmaceuticals in Q3 2013 and has held it in 51 quarters since.
- Royal Bank of Canada's Inovio Pharmaceuticals position peaked at $750K in Q4 2021.
- 103 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2026.
Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.